liposomal doxorubicin + cyclophosphamide vs docetaxel + cyclophosphamide

This entry refers to a comparative evaluation of two chemotherapy regimens used primarily in the treatment of breast cancer, especially metastatic or early-stage disease. The first regimen combines liposomal doxorubicin (often pegylated, e.g., PLD) with cyclophosphamide. Liposomal doxorubicin is an anthracycline antibiotic encapsulated in liposomes to reduce cardiotoxicity and improve pharmacokinetics; it intercalates DNA and inhibits topoisomerase II, leading to apoptosis in rapidly dividing cells. Cyclophosphamide is an alkylating agent that crosslinks DNA, inhibiting cell replication. The second regimen combines docetaxel (a taxane that stabilizes microtubules and prevents cell division) with cyclophosphamide. Both regimens are administered intravenously on a cyclical basis and are standard options for various settings in breast cancer therapy.